Current evidence and practical guidance for the use of sodium–glucose co-transporter-2 inhibitors in type 2 diabetes
Year: 2021
Type: article
Abstract: BACKGROUND: The burden of type 2 diabetes (T2D) and its associated complications continues to grow in Australia. In recent years, sodium-glucose co-transporter-2 (SGLT2) inhibitors have become a key component of diabetes care with rapid uptake into routine clinical practice. There is growing evidence of their clinical efficacy, but also potential adverse effects. OBJECTIVE: The aim of this article is to review the use of SGLT2 inhibitors in T2D by exploring data surrounding clinical efficacy and safety as well as providing practical advice for prescribing clinicians. DISCUSSION: SGLT2 inhibitors have multiple metabolic benefits including reducing glycated haemoglobin, weight and blood pressure. Additionally, there are strong cardiovascular benefits and renoprotective effects in selected populations. Current evidence suggests that SGLT2 inhibitors should be considered for the secondary prevention of cardiovascular disease and to delay progression of early chronic kidney disease in people with T2D. Clinicians should also be aware of common side effects and potential rare severe complications.
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: Improving diabetes-related health outcomes with Aboriginal and Torres Strait Islander people across the lifecourse, Intergenerational metabolic health in Indigenous and non-Indigenous Australians – Understanding trends, determinants and outcomes, The Epidemiology of Diabetes Complications: Identifying New Risk Factors and Population Trends
OpenAlex ID: W3149259697
